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Regulatory enhancer elements in solid tumours remain poorly characterized. Here we apply
micro-scale chromatin proﬁling to survey the distal enhancer landscape of primary gastric
adenocarcinoma (GC), a leading cause of global cancer mortality. Integrating 110 epigenomic
proﬁles from primary GCs, normal gastric tissues and cell lines, we highlight 36,973
predicted enhancers and 3,759 predicted super-enhancers respectively. Cell-line-deﬁned
super-enhancers can be subclassiﬁed by their somatic alteration status into somatic gain, loss
and unaltered categories, each displaying distinct epigenetic, transcriptional and pathway
enrichments. Somatic gain super-enhancers are associated with complex chromatin
interaction proﬁles, expression patterns correlated with patient outcome and dense
co-occupancy of the transcription factors CDX2 and HNF4a. Somatic super-enhancers are
also enriched in genetic risk SNPs associated with cancer predisposition. Our results reveal a
genome-wide reprogramming of the GC enhancer and super-enhancer landscape during
tumorigenesis, contributing to dysregulated local and regional cancer gene expression.
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A
berrant gene expression patterns are a universal hallmark
of human malignancy driving clinically important traits
such as proliferation, invasion and metastasis1. Cancer
transcriptomes can be reprogrammed by genomic alterations
(somatic mutations, copy number alterations and structural
variations) affecting signalling molecules and transcription factors
(TFs)2. Besides protein-coding genes, cis-regulatory elements in
noncoding genomic regions can also inﬂuence transcriptional
programs by facilitating or restricting TF accessibility3.
Distinct regulatory element classes are deﬁned by different
epigenomic marks, involving DNA methylation, histone
methylation/acetylation and other combinations4. For example,
promoters are marked by histone H3 lysine 4 tri-methylation
(H3K4me3), enhancers by H3K4me1, active regulatory
elements by H3K27ac and repressive features by H3K27me35,6.
A growing number of studies are now highlighting the
signiﬁcance of histone modiﬁcations in the development and
maintenance of disease states4,6,7. It has also been proposed that
because epigenetic modiﬁcations are more stable than RNA
transcripts, histone modiﬁcation proﬁling may offer a better
measure of transcriptional status than RNA sequencing8.
Enhancers are regulatory elements localized distal to promoters
and transcription start sites (TSSs). Occupying 10–15% of the
human genome9, enhancers play important roles in cell identity
and tissue-speciﬁc expression by regulating one or more genes at
large distances (41Mb)10. Recent studies have demonstrated
that enhancers can be subdivided into different classes, with one
such class comprising enhancer clusters occurring in close
proximity, referred to as ‘super-enhancers’11,12. Compared to
typical enhancers, super-enhancers are larger in size, exhibit
higher TF binding densities and are strongly associated with
key cell identity regulators, similar to locus control regions13,
DNA methylation valleys14, transcription initiation platforms15
and stretch enhancers16. Super-enhancers are also enriched in
disease-associated genetic variants11, are acquired by cancer cells
at key oncogenes11, and importantly are more sensitive to
therapeutic perturbation12.
The emerging importance of super-enhancers in human
disease, coupled with their exquisite tissue-speciﬁcity, raises a
need for comprehensive super-enhancer catalogues of different
cell types and disease conditions. In cancer, such super-enhancer
catalogues are indeed emerging, for both haematological and solid
malignancies11,17. However, most of these studies to date have
relied on in vitro cultured cancer cell lines, which have two
limitations. First, in vitro cell lines are known to experience
substantial epigenomic alterations after repeated passaging18.
Second, for many cancer cell lines, matched normal counterparts
are frequently not available, complicating the ability to identify
true tumor-speciﬁc somatic alterations.
Gastric cancer (GC) is the ﬁfth most common cancer worldwide
and the third leading cause of global cancer mortality19. Most GCs
are adenocarcinomas, and molecular studies have revealed key
genetic alterations associated with gastric malignancy, including
mutations in chromatin modiﬁer genes such as ARID1A, and
ampliﬁcations in HER2, FGFR2 and MET20. In contrast to genetic
alterations, our knowledge of the GC epigenome remains poorly
understood, with current knowledge largely conﬁned to patterns of
aberrant DNA methylation21.
To address the role of histone modiﬁcations in GC, we recently
reported a proof-of-concept study employing micro-scale
chromatin proﬁling (Nano-ChIPseq) to survey histone
modiﬁcations in primary GCs4. In this study, we extended this
effort to characterize the GC super-enhancer landscape. By
integrating predicted super-enhancer data from both cell lines
and primary tumours, we provide evidence that like enhancers,
predicted super-enhancers are heterogeneous and can be further
subclassiﬁed into biologically distinct subgroups with impact on
tumour-speciﬁc gene expression, cancer hallmarks and disease
genetic variation. We also found that in GCs, predicted
super-enhancers exhibiting somatic gain are associated with
CDX2 and HNF4a occupancy. Taken collectively, our results
reveal a pervasive reprogramming of the gastric super-enhancer
landscape during tumourigenesis, underpinning wide-spread
alterations in cancer gene expression.
Results
Distal predicted enhancer landscapes of GC cell lines. Using
Nano-ChIPseq, we generated 110 chromatin proﬁles from 19
primary GCs, 19 matched normal gastric tissues and 11 GC cell
lines covering multiple histone H3 modiﬁcations (H3K27ac,
H3K4me3, H3K4me1) (average B3.3 107 reads per proﬁle).
Clinical information and molecular classiﬁcation of the primary
GCs is presented in Supplementary Table 1, sequencing statistics
in Supplementary Data 1 and clinico-pathological details for the
GC lines in Supplementary Table 2. Our series included 10 gland
forming adenocarcinomas (53%, intestinal type), 6 samples with
highly inﬁltrating isolated cells (32%, diffuse type) and 3 GC
samples (15%) of mixed histology. More than 60% of the tumours
(n¼ 12) were Stage 3 or above (AJCC 7th edition). We performed
extensive quality control analysis of the Nano-ChIPseq
data, including variations in mapping quality ﬁlters, analysis of
biological replicates and promoter ChIP-enrichment, and
assessment by the quality control software CHANCE (CHip-seq
ANalytics and Conﬁdence Estimation22). Increasing mapping
threshold stringencies (from MAPQ Z10 to 20) did not
appreciably alter mapping statistics: 490% of the total
mapped reads were retained, and 85% of ChIP-enriched
peaks and 98% of predicted enhancers were rediscovered
respectively (Supplementary Fig. 1). Histone peak concordance
between biological replicates of KATO-III cells generated by
Nano-ChIPseq, and also against independent KATO-III H3K27ac
data generated by conventional ChIP-seq23, conﬁrmed high
reproducibility (overlaps of B85 and B90%) (Supplementary
Fig. 2). Comparisons of input and input-corrected H3K27ac and
H3K4me3 signals at 1000 promoters associated with highly
expressed protein-coding genes revealed successful enrichment in
48 out of 50 (96%) H3K27ac and 42 out of 42 (100%) H3K4me3
libraries respectively. CHANCE analysis of ChIP enrichment,
particularly for H3K4me1 (which is depleted at promoters),
revealed that the large majority (85%) of samples exhibited
successful enrichment (Methods). These results demonstrate
the good technical quality of the Nano-ChIPseq cohort.
Besides Nano-ChIPseq, the samples were also processed for
DNA methylation analysis (Inﬁnium HumanMethylation 450K
BeadChip arrays), copy number analysis (Affymetrix SNP arrays)
and Illumina RNA-sequencing.
We chose to use GC cell lines as a discovery cohort to discover
cancer-associated distal enhancers in GC, as cell lines are purely
epithelial in nature, have the highest data quality, and because
previous studies have shown that stromal contamination in
primary tissues can inﬂuence genomic results24. We also focused
on recurrent epigenetic alterations present in multiple GC
samples, which reduces the introduction of ‘private’ epigenetic
alterations associated with individualized cell line features. First,
we mapped genome-wide cis-regulatory elements based on
H3K27ac signals, previously shown to mark active promoters
and enhancers4. To enrich for enhancer elements, we focused on
H3K27ac signals located distant from known annotated
TSSs (TSSs; 42.5 kb) in accordance with previous studies25
(Fig. 1a). We then further reﬁned the enhancer predictions
using aggregated H3K4me1 and H3K4me3 data, excluding
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from analysis predicted enhancers exhibiting high
H3K4me3/H3K4me1 log ratios (42.4)26. Using this
approach, we identiﬁed 3,017 to 14,338 putative distal
enhancers in the GC lines (Fig. 1b), with an average genomic
footprint of 25Mb/line.
In total, we detected 36,973 predicted distal enhancer regions,
spanning B140Mb or approximately 5% of the human genome.
The predicted enhancers exhibited a bimodal H3K27ac signal
distribution11 (Fig. 1b), were depleted of H3K4me3 and were
enriched in H3K4me1 signals, similar to enhancer modiﬁcation
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proﬁles reported in previous studies6 (Fig. 1c and Supplementary
Fig. 3). Visual comparison of selected H3K27ac-enriched regions
revealed that some regions are active in multiple lines
(‘recurrent’) while other regions are active in only one line
(‘private’). These observations are similar to previous results in
both lymphoblastoid27 and colon carcinoma cell lines7.
Approximately 47% of the predicted enhancers were recurrent,
exhibiting activity in at least two GC cell lines (Fig. 1d). The
percentage of recurrent enhancers was signiﬁcantly lower
compared to promoters (67 versus 47%, Po2.2 10 16, one-
sided proportion test), indicating that enhancer activity is highly
variable across GC cell lines.
We validated the predicted enhancers by integrating publicly
available epigenomic datasets. Using DNase I hypersensitivity
(DHS) data of normal gastric tissues from the Epigenome
Roadmap, we found that DHS signal distributions (log-
transformed RPKM) at predicted enhancers were signiﬁcantly
greater than randomly selected regions (Po2.2 10 16,
one-sided Welch’s t-test; Fig. 1e, Methods), indicating that
predicted enhancers are associated with open chromatin. When
compared against DHS and H3K27ac data of nine different tissue
and cellular categories28, predicted enhancers exhibited the
highest overlap with DHS-positive and H3K27ac-positive
regions from digestive and epithelial tissues (fetal intestine,
gastric and small intestine), and were distinct from non-epithelial
tissue types such as blood and T-cells (Fig. 1f). Supporting their
regulatory potential, 54% of the predicted enhancers (n¼ 20,127)
were associated with EP300 binding sites (Fig. 1g; Po0.001,
empirical test), and 92% with TF binding sites. At the DNA
sequence level, 63% of the predicted enhancer sequences were
evolutionarily conserved (Fig. 1h; Po0.0001, empirical test).
Super-enhancers are enriched in cancer signatures.
‘Super-enhancers’ or ‘stretch-enhancers’ refer to a sub-population
of enhancers displaying extended physical proximity (þ /
12.5 kb), and have been proposed to be critical for cell identity
and maintenance of healthy or disease state11,12. Using the
ROSE algorithm12, we identiﬁed 133 to 1318 predicted super-
enhancers per GC line, collectively encompassing 3,759
non-redundant-predicted super-enhancers (Fig. 2a). We thus
estimate that about 10% of GC cell-line-predicted enhancers are
associated with predicted super-enhancer activity, consistent with
the 4–19% estimated by other studies11. Compared to predicted
typical enhancers, predicted super-enhancers exhibited a
signiﬁcantly greater tendency to be recurrent (Fig. 2b; one-sided
proportion test, Po2 10 16), with 3,345 predicted super-
enhancers being active in at least two GC cell lines. We observed
predicted super-enhancers associated with known protein-coding
GC oncogenes (for example, MYC and KLF5; Supplementary
Fig. 4a) and also at non-protein-coding gene regions such as at
the MALAT1 locus (Fig. 2c), which encodes a long-noncoding
RNA (lncRNA) recently shown to promote GC proliferation29.
We assigned predicted super-enhancers to target genes based
on regions exhibiting the nearest active TSS (deﬁned as H3K27ac
enrichment at promoters, within 500 bp of an annotated TSS).
This strategy has been previously used in other studies11.
Consistent with other reports26, only 53% of our
predicted super-enhancer/gene interactions involved the closest
proximal gene (see Methods, mean distance 76 kb). We
validated the predicted super-enhancer/gene assignments
using three orthogonal interaction data sets: (i) pre-determined
interactions predicted by PreSTIGE30, (ii) GREAT31, and
(iii) published RNAPII ChIA-PET data (encodeproject.org,
GSE72816). Of 2,677 predicted interactions with protein-coding
genes, 88% were supported by at least one of these three data
sets (Supplementary Fig. 5). This number is likely a lower limit as
the biological samples for the latter validation data in (i)-(iii) did
not involve gastric tissues (see subsequent sections). To
understand biological themes associated with the predicted
super-enhancers, we applied GOrilla pathway analysis32 and
found that biological processes plausibly related to cancer
development, such as regulation of signal transduction,
programmed cell death and cell proliferation were strongly
associated with predicted super-enhancer linked genes (P-values
6.7 10 22 to 2.3 10 13, hypergeometric test by GOrilla)
(Fig. 2d). Many of these processes (eg, regulation of programmed
cell death, cell proliferation) remained signiﬁcantly associated
when the recurrent predicted super-enhancers were analysed
by GREAT, indicating that that these enrichments are not due
to biases toward genes ﬂanked by large intergenic regions
(Supplementary Fig. 6). Similar analyses employing genes
linked to the top predicted typical enhancers yielded a lesser
degree of enrichment (Fig. 2d). Predicted super-enhancer
associated genes were also enriched for oncogenes
(P¼ 1.7 10 8, one-sided Fisher’s exact test). When correlated
to gene expression, genes associated with recurrent predicted
super-enhancers and typical enhancers were both signiﬁcantly
correlated with RNA expression (Supplementary Fig. 4b).
Super-enhancer heterogeneity in primary tumours. To
determine which cell-line-predicted super-enhancers are also
associated with somatic alterations in vivo, we compared
H3K27ac enrichment levels for these regions across 19 primary
GCs and matched normal gastric tissues. While previous studies
have suggested the presence of distinct molecular subtypes of
GC33–35, due to limited sample sizes we elected in the current
study to focus on predicted enhancer differences conserved
in multiple GC tissues relative to matched normal tissues
(see Discussion). Prior to analysis, we conﬁrmed that the
primary gastric normal samples were indeed reﬂective of
gastric epithelia, by correlating against published proﬁles
(Supplementary Discussion). Of 3,759 cell-line-predicted
super-enhancers, two-thirds exhibited differential enrichment
between tumours and matched normal samples (Fig. 3a,
Supplementary Data 2, referred to as somatically altered
Figure 1 | Distal Predicted Enhancer landscapes of GC cell lines. (a) Histone proﬁles of OCUM-1 and NCC59 GC cells show enrichment of H3K27ac and
H3K4me3 around the DDX47 TSS. A predicted enhancer element exhibiting H3K27ac enrichment and 42.5 kb away from the DDX47 TSS was identiﬁed.
(b) Snapshot of distal H3K27ac proﬁles in 4 of the 11 GC cell lines, visualizing the activity of the top 2,000 predicted enhancers and the genome-wide
average H3K27ac signal around the predicted enhancers. (c) Genome-wide average H3K4me3 signals around predicted enhancers and active TSSs in GC
cell lines. (d) Recurrence rates of regulatory elements. Data presented are the mean percentage þ / standard deviation of common regulatory elements
(enhancer—blue; promoter—green) found in two or more gastric cancer cell lines, as a function of number of cell lines. (e) Chromatin accessibility of
predicted enhancers versus randomly selected regions. DNase I hypersensitivity (DHS) data from normal gastric tissues28 was used as a surrogate. The
distribution of DHS signals was tested using a one-side Welch’s t-test for statistical signiﬁcance. (f) Percentage of overlap between predicted enhancers,
chromatin accessible regions (denoted as DHSþ , x axis) and active regulatory elements (denoted as H3K27acþ , y axis) from 50 epigenomic proﬁles
originating from nine different tissue/cell categories. (g) Percentage of predicted enhancers overlapping with EP300 and transcription factor binding sites.
(h) Distribution of maximum Phast scores (a measure of DNA sequence conservation) in predicted enhancers and randomly selected regions.
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thereafter). Close to half of the predicted super-enhancers
(n¼ 1748; 47%) exhibited somatic gain in two or more primary
GCs (4 2-fold enrichment in tumour, minimum 0.5 RPKM
difference), and principal component analysis (PCA) using these
gained predicted super-enhancers conﬁrmed separations between
GC and matched normal tissues (Fig. 3b). Supporting the
consistency of these results, the vast majority of these recurrent
somatic gain predicted super-enhancers (85%, 41.5-fold change
threshold) were rediscovered when using only those
normal/tumour (N/T) primary pairs passing all quality control
criteria (14 pairs, see earlier). Unexpectedly, despite their activity
in cancer cell lines, a substantial proportion of predicted
super-enhancers (18%) were associated with somatic loss rather
than gain in primary GCs (Fig. 3a). It is possible that these
latter regions may represent regions epigenetically silenced in
primary tumours but reactivated in cell lines during in vitro
culture (Supplementary Fig. 7a). In all, 11% of the predicted
super-enhancers (n¼ 416) exhibited unaltered H3K27ac levels
between GCs and normal tissues (Fig. 3a, Supplementary Fig. 7b),
consistent with these regions not being cancer-associated but
related to ‘housekeeping’ or general tissue functions. Finally, 21%
(n¼ 808) of cell-line-predicted super-enhancers did not
exhibit sufﬁcient H3K27ac enrichment (RPKMo0.5) in
primary samples for analysis (Supplementary Fig. 7c).
Interestingly, this class was also associated with low recurrence
in GC lines (Fig. 3a—histogram in black). Taken collectively,
these results demonstrate that predicted super-enhancers derived
from cell lines can be further subclassiﬁed using histone
modiﬁcation data from primary tumours and matched normal
controls into at least three categories—somatic gain, somatic
loss and unaltered. A list of the top 100 somatic predicted
super-enhancers is presented in Supplementary Data 2.
Supporting their biological distinctiveness, predicted
super-enhancers belonging to the three categories also exhibited
other epigenetic differences in vivo. For example, predicted
super-enhancer alterations in H3K27ac were similarly correlated
with H3K4me1 enhancer mark alterations (Fig. 3c), and at the
DNA methylation level somatic gain predicted super-enhancers
exhibited signiﬁcantly lower DNA methylation levels, while
somatic loss super-enhancers exhibited increased DNA
methylation (P¼ 3.8 10 229, one-sided Welch’s t-test).
Unaltered predicted super-enhancers occupied an intermediate
range (Fig. 3d). As a visual example, we observed decreased DNA
methylation (indicated by a lower beta value) in GC T2000721
compared to its matched normal (N2000721), mapping to a
somatic gain predicted super-enhancer at the ABLIM2 locus
(Fig. 3e). In contrast, somatic loss of H3K27ac signals at a
SLC1A2 predicted super-enhancer in T2000639 showed increased
DNA methylation compared to N2000639 (Fig. 3f). These results
further support the biological and molecular heterogeneity of
predicted super-enhancers in gastric tissues.
Super-enhancers exhibit complex chromatin interactions.
Integration with copy number data revealed that the majority of
somatic predicted super-enhancers are localized to copy number
neutral regions (Supplementary Fig. 8a-c, Supplementary
Discussion). To examine associations between predicted
super-enhancers and gene expression, we interrogated RNA-seq
information from the same primary samples, using the same
predicted super-enhancer/gene assignments as the previous
pathway analyses (Fig. 2). Somatic gain predicted super-
enhancers were associated with elevated gene expression relative
to matched normal samples, while somatic loss predicted
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super-enhancers were associated with decreased expression
(Po2.2 10 16, one-sided Welch t-test; Fig. 4a).
Previous research has also shown that enhancers are often
involved in long-range chromatin interactions that may inﬂuence
the expression of multiple genes10,26. To identify long-range
interactions associated with somatic predicted super-enhancers in
GC, we applied Capture-C technology36 to survey interactions for
36 predicted super-enhancers, selected from regions exhibiting
both recurrent somatic gains in primary tumour samples and also
demonstrating activity in GC lines. Analysing three GC cell lines
(OCUM-1, SNU16, KATO-III), we probed multiple genomic
locations (n¼ 92, referred to as ‘capture points’) across the 36
predicted super-enhancers, identifying 88 capture points with
signiﬁcant interactions (Qo0.05, r3Cseq package37). Fig. 4b
depicts 12 representative predicted super-enhancers covering 20
capture points. On average, each predicted super-enhancer
exhibited 20–26 and 5–7 interactions with other genomic
locations and promoters respectively. The average distance
between capture points and detected interactions was
approximately 17.0 kb (standard deviation: 30.5 kb). We also
identiﬁed longer-range interactions, including a predicted
super-enhancer interaction with the TM4SF4 promoter at a
distance of B100 kb in OCUM-1 cells (Supplementary Fig. 9).
Notably, for regions with informative interaction data, the
availability of experimental Capture-C information also allowed
us to further validate 93% (n¼ 62) of our original predicted
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Figure 3 | Somatic predicted super-enhancers in primary GCs and matched normal samples. (a) Activity of cell-line-derived predicted super-enhancers
in 19 primary tumour and matched normal samples. H3K27ac predicted super-enhancer signals in units of column-transformed RPKM values (z-score)
were visualized. The frequency of active predicted super-enhancers in GC lines in vitro is presented as the top histogram (black, above the heatmap).
Predicted super-enhancers were categorized into somatic gain, somatic loss, unaltered and inactive. In each category, the predicted super-enhancers were
ordered (left to right) by their decreasing mean difference between the tumour and the normal samples. (b) Principal component analysis using recurrent
somatic gain predicted super-enhancer signals establish a separation between tumour and normal samples. (c) Differences in H3K4me1 (T-N) signals
(RPKM) using H3K4me1 proﬁles from ﬁve tumour and matched normal samples in three predicted super-enhancer categories: somatic gain, somatic loss
and unaltered. *Po2.2 10 16, one-sided Welch t-test. (d) Differential b values in predicted super-enhancers indicate the state of methylation:
hypermethylation (40) or hypomethylation (o0) between tumours and matched normal samples. (e) DNA hypomethylation in a somatic gain predicted
super-enhancer at the ABLIM2 locus. (f) DNA hypermethylation in a somatic loss predicted super-enhancer at the SLC1A2 locus.
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Figure 4 | Associations between somatic predicted super-enhancers with gene expression and chromatin interactions. (a) Correlation between log-
transformed fold changes in gene expression between different classes of predicted super-enhancers (unaltered, somatic gain, somatic loss) and predicted
target gene expression. (b) Interaction heat map from 20 capture points covering 12 somatic gain predicted super-enhancers. Each ring represents a proﬁle
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using two capture points, #33 and #34 by Capture-C. Summarized interactions (Qo0.05, r3Cseq) are presented as the last track. Two constituent
predicted enhancers, e1 and e2, were deleted independently in SNU16 cells using CRISPR/Cas9 genome editing. (d) Correlation between predicted
super-enhancer activity and long-range interactions. Long-range interactions (green triangle) to the SLC35D3 promoter were detected with a predicted
super-enhancer active in SNU16 and OCUM-1 cells. Such interactions were not observed in KATO-III cells where the predicted super-enhancer was also
not detected.
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super-enhancer/gene interactions. Integration of expression data
from the cell lines revealed that B70% of the interacting
promoters are associated with detectable gene expression
(FPKM40).
As a representative example, Fig. 4c depicts the long-range
interaction landscape of the CLDN4 genomic region in SNU16 cells
(see Supplementary Fig. 10 for other examples). This region was
selected as CLDN4 expression has been previously associated with
GC progression and prognosis38, and recurrent gain of the CLDN4
predicted super-enhancer was observed in multiple primary GCs
(Supplementary Fig. 8d). Speciﬁcally, we sought to investigate
interactions involving two predicted sub-super-enhancer regions
exhibiting high H3K27ac signals and also CDX2 and HNF4a
co-binding (see later). Besides interactions with the CLDN4
promoter, interactions were also detected with other distal
promoters (up to B100 kb) such as WBSCR27, CLDN3,
ABHD11 and ABHD11-AS1. ABHD11-AS1 is a long non-coding
RNA was previously shown to be highly expressed in gastric
cancer39. To validate the Capture-C data, we also performed
circularized chromosome conformation capture assays (4C)40 on
four selected predicted super-enhancers in two GC lines
(OCUM-1, SNU16) (Supplementary Fig. 11). We observed a
concordance between Capture-C and 4C data of 75%, similar to
concordance rates between 4C experimental replicates37
(Supplementary Fig. 12). Due to the signiﬁcantly greater depth of
4C sequencing, we also identiﬁed additional interactions, such as a
long-range interaction between a predicted super-enhancer and the
KLF5 promoter at a distance ofB350 kb (Supplementary Fig. 11b).
Previous reports have suggested that certain long-range
interactions are associated with super-enhancer activity, while
other interactions are more invariant and reﬂective of cell
lineage10,41. In agreement with these ﬁndings, of 22 (out of 36)
predicted super-enhancers displaying differential activity between
the GC lines, four predicted super-enhancers exhibited a good
correlation between predicted super-enhancer activity and the
presence of long-range interactions (Fig. 4d and Supplementary
Fig. 13). For the remaining 18 predicted super-enhancers,
long-range interactions were observed independent of predicted
super-enhancer activity.
To investigate a causal role between the predicted super-
enhancers and gene expression, we used CRISPR/Cas9 genome
editing to delete two enhancer regions (e1 and e2; see Fig. 4c)
within the CLDN4 predicted super-enhancer region. After
conﬁrming CRISPR deletion efﬁciencies in OCUM-1 and SNU16
cells (Supplementary Fig. 14a–c), we compared predicted target
gene expression levels between enhancer-deleted and wild-type
cells by RT-qPCR. In both cell lines, e1 CRISPR-deletion caused
downregulation of multiple CLDN4 locus genes, including
ABHD11, CLDN3 and CLDN4 (CLDN4 in SNU16 cells,
Supplementary Fig. 14d). In a similar fashion, we also observed
ABHD11, CLDN3 and CLDN4 downregulation after e2 deletion in
OCUM-1 cells (e2-deleted SNU16 cells were not viable, hence
precluding gene expression analysis; Supplementary Fig. 14e). To
extend these results, we then CRISPR deleted two other predicted
enhancer elements (e3 and e4) from the ELF3 predicted super-
enhancer in OCUM-1 cells (Supplementary Figs 11a and 14c), as
ELF3 has been reported as a cancer gene in several malignancies42.
Both e3 and e4 deletion resulted in downregulation of multiple
ELF3 locus genes including ARL8A, ELF3, RNPEP and TIMM17A
(Supplementary Fig. 14f). Taken collectively, these results support
a causal relationship between predicted super-enhancer activity
and tumour gene expression.
Somatic super-enhancers and clinical outcome. To further
explore the biological and clinical relevance of predicted
super-enhancer heterogeneity, we performed cancer hallmark
analysis categorized by somatic modiﬁcation status (gained, lost,
unaltered). Of ten cancer hallmarks11, somatic gain predicted
super-enhancers were signiﬁcantly enriched in genes related to
invasion (P¼ 8.6 10 11, one-sided Fisher’s exact test),
angiogenesis (P¼ 2.4 10 4, one-sided Fisher’s exact test) and
cell death resistance (P¼ 7.8 10 3, one-sided Fisher’s
exact test), exceeding somatic loss and predicted unaltered
super-enhancers by an order of magnitude (Fig. 5a). These
results suggest that somatic gain predicted super-enhancers
may be involved in traits associated with aggressive GC. When
compared against predicted super-enhancer proﬁles of 86 cell and
tissue samples,460% of somatic gain predicted super-enhancers
in GC exhibited high tissue-speciﬁcity. We also observed
signiﬁcant overlaps (Po0.001, empirical test) with predicted
super-enhancers previously described in other cancer types,
such as colorectal, breast, cervical and pancreatic cancer
(Supplementary Fig. 15), suggesting that certain GC-associated
predicted super-enhancers may also be active in other
cancer types.
We next asked if gene expression patterns associated with the
somatic gain predicted super-enhancers might be associated with
GC patient survival. We selected genes associated with the top 50
predicted super-enhancers, from regions exhibiting both
recurrent somatic gains in multiple GC patients, and also
exhibiting the highest correlations with target gene expression.
Supporting the validity of this approach, several genes selected in
this manner were observed to have been previously shown to be
overexpressed in GC, such as CDH1743 and CCAT144. The gene
list also included potentially novel GC associated genes, such as
SMURF1 and LINC00299 (Supplementary Table 3).
We performed survival analysis across three non-Asian GC
and four Asian GC cohorts comprising of 848 GC patients.
Patients with GCs exhibiting high expression of predicted
super-enhancer associated genes showed poor overall survival
compared with GC samples where these genes are relatively lowly
expressed (Fig. 5b, P¼ 1.8 10–2, log rank test). Supporting the
robustness of this association, the relationship with patient
survival remained signiﬁcant even after varying the number of
predicted super-enhancers (n¼ 30, P¼ 0.02, log rank test; n¼ 60,
P¼ 0.03, log rank test). In a multivariate analysis, the association
with survival also remained statistically signiﬁcant even after
adjusting for other risk factors, such as age, stage, patient
locality and histological subtype (P¼ 0.044, Wald test).
These data indicate that genes driven by somatic gain predicted
super-enhancers in GC may be clinically important.
To address the relationship between the different predicted
super-enhancer categories and disease risk, we considered previous
genome-wide association studies (GWAS) studies showing that
disease-associated single-nucleotide polymorphisms (SNPs) are
enriched at regulatory elements11,45. We mapped catalogues of
disease-associated SNPs reported from 1,470 GWAS against those
predicted super-enhancers exhibiting recurrent somatic alterations
(gained or lost) or unaltered predicted super-enhancers. Somatic
predicted super-enhancers were enriched for disease-risk SNPs
associated with various cancers (prostate, colorectal, breast;
enrichment ratio¼ 3.0–7.2; Po4.4 10 3, chi-square test) and
gastrointestinal diseases such as ulcerative colitis (enrichment
ratio¼ 3.3; P¼ 5.2 10 4, chi-square test) (Fig. 5c). In
contrast, unaltered predicted super-enhancers did not exhibit
similar enrichments. Unexpectedly, we also observed enrichment
of multiple sclerosis SNPs in somatic altered predicted
super-enhancers (enrichment ratio¼ 4.3; P¼ 1.8 10 7,
chi-square test), suggestive of interconnections between cancer
and autoimmune response46. To explore if predicted
super-enhancer disease SNPs might be associated with local
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12983
8 NATURE COMMUNICATIONS | 7:12983 | DOI: 10.1038/ncomms12983 | www.nature.com/naturecommunications
changes in chromatin modiﬁcation, we then focused on SNPs
associated with colorectal cancer reported in at least two studies
and also exhibiting heterozygosity in at least 1/3 of the GC patients
(see Discussion). Two SNPs fulﬁlled these criteria (rs10411210
and rs10505477). Samples with the rs10411210 SNP exhibited
signiﬁcantly higher H3K27ac signals in tumours versus matched
normals (Fig. 5d; P¼ 0.01, one-sided Welch’s t-test), and a
similar trend was also observed in samples with the rs10505477
SNP (P¼ 0.07, one-sided Welch’s t-test). Such associations
suggest a relationship between disease-associated risk SNPs and
cancer-associated histone modiﬁcation.
Super-enhancers exhibit dense TF occupancy. Finally, we
explored trans-acting factors associated with somatic gain predicted
super-enhancers. Concordant with previous studies47, GC predicted
super-enhancers exhibited signiﬁcantly enriched ENCODE TF
binding proﬁles compared to other genomic regions, supporting the
former as TF ‘hot-spots’ (Po2.2 10 16, one-sided proportion
test). Interrogating the ReMap database48, we then identiﬁed
speciﬁc TFs associated with the different predicted super-enhancer
categories. Both somatic gain and unaltered predicted
super-enhancers exhibited enrichments in CEBPB, MYC and
FOXA1 binding. However, among the top ten enriched TFs,
CDX2 exhibited elevated enrichment in somatic gain predicted
super-enhancers (rank #2), with an approximately 30% increased
binding density compared to unaltered predicted super-enhancers
(rank #8) (Fig. 6a,b).
As TFs often act in a cooperative manner, we then identiﬁed
potential CDX2 partners by using HOMER49, a de novo motif
discovery algorithm. HOMER analysis identiﬁed HNF4a, KLF5
and GATA4 binding motifs associated with CDX2 binding
(Fig. 6c). We also analysed CDX2 co-binding motifs using
PScanChIP50 with JASPAR 2016. Using PScanChIP, we predicted
367 proteins as potential CDX2 partners, once again including
HNF4a, KLF5 and GATA4 (Supplementary Data 3). Gene
co-expression analysis revealed that HNF4a (Spearman
correlation, r¼ 0.80) and KLF5 (r¼ 0.58) are the most strongly
correlated candidates with CDX2 expression, suggesting that
HNF4a and KLF5 may be likely CDX2 partners (Fig. 6d).
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Notably, CDX2 has been previously identiﬁed in GC as a driver of
intestinal metaplasia51, and KLF5 and GATA4/6 have been
previously reported as oncogenic TFs in GC that cooperate to
upregulate HNF4a52.
To experimentally conﬁrm genomic co-occupancy of CDX2
with HNF4a (the highest correlated factor), we performed CDX2
and HNF4a ChIP-seq on OCUM-1 gastric cells, and integrated the
TF binding locations with predicted super-enhancer locations. In
OCUM-1 cells, CDX2 and HNF4a binding summits (qo0.01,
MACS2) exhibited high co-occurrence (500bp window), with 76%
of CDX2 binding co-occurring with HNF4a (known as
CDX2/HNF4a sites) (Fig. 6e). Comparing the top 50% of high
CDX2-expressing GCs against the lowest 50%, we found that in the
former samples, recurrent somatic gain predicted super-enhancers
were indeed associated with higher CDX2 binding densities (123
bindings per million base pair, Mbp versus 92 Mbp; see Methods).
CDX2/HNF4a sites were preferentially localized to somatic gain
predicted super-enhancers relative to unaltered predicted super-
enhancers (P¼ 2.4 10 4, chi-square test), and both CDX2 and
HNF4a binding signals were increased at somatic gain predicted
super-enhancers relative to unaltered predicted super-enhancers
(Fig. 6f). Similar CDX2 and HNF4a ChIP-seq results were also
obtained in SNU16 cells (Supplementary Fig. 16a). This result
indicates that somatic gain predicted super-enhancers in GC are
associated with CDX2 and HNF4a occupancy.
To test if CDX2 and HNF4a might play a role in GC
super-enhancer maintenance, we performed silencing of each TF,
either singly or both factors simultaneously, followed by
genome-wide H3K27ac proﬁling. Depletion of either factor, either
individually or in combination, did not induce global changes in
H3K27ac in OCUM-1 cells (Supplementary Fig. 16b). However,
CDX2 and HNF4a-silencing led to speciﬁc H3K27ac alterations in
9.7Mb and 4.3Mb of the genome respectively, and double-TF
knockdown induced signiﬁcantly greater H3K27ac depletion
(P¼ 3.4 10 29 and 1.2 10 88 compared to CDX2 and
HNF4a-alone, one-sided Wilcoxon rank sum test)
(Supplementary Fig. 16c). For both single-TF and double-TF
silencing, H3K27ac depletion occurred more prominently at
somatic gain predicted super-enhancers compared to predicted
typical enhancers, suggesting a heightened sensitivity of super-
enhancer activity to TF depletion (Fig. 6g, Supplementary Fig. 16d,
Supplementary Data 4; P¼ 5.3 10 7; P¼ 1.8 10 17;
P¼ 1.5 10 10 for CDX2, HNF4a and CDX2/HNF4a
respectively, one-sided Wilcoxon rank sum test). Supporting the
speciﬁcity of these effects, H3K27ac depletion at predicted
super-enhancers was more pronounced at regions centred at
CDX2 or HNF4a binding sites, particularly at sites co-occupied by
both factors (Fig. 6h). Similar results were also obtained in SNU16
cells (Supplementary Fig. 16e). Next, to assess relationships
between predicted super-enhancers and gene expression, we
focused on predicted super-enhancers exhibiting H3K27ac deple-
tion after TF silencing. We observed that 460% of predicted
super-enhancer target genes also exhibited reduced expression
after TF silencing (siCDX2, P¼ 4 10 4, empirical test; siHNF4a,
Po1 10 4, empirical test; si(CDX2/HNF4a), Po1 10 4,
empirical test; Supplementary Fig. 16f). This proportion signiﬁ-
cantly exceeded that expected by chance, as assessed by
permutation analysis (Methods). Taken collectively, these results
support a functional requirement for CDX2 and HNF4a in GC
super-enhancer maintenance.
Discussion
GC is a clinically heterogeneous disease, and besides surgery and
chemotherapy, only traztuzumab (anti-HER2) and ramucirumab
(anti-VEGFR2) are approved clinically with other molecularly
targeted agents proving unsuccessful to date20. Epigenomic
deregulation has emerged as an important pathway in gastric
tumorigenesis, with chromatin modiﬁer genes (eg, ARID1A)
being frequently mutated in GC53,54 and epigenetic alterations
associated with gastric pre-malignancy55. To date however, the
vast majority of GC epigenomic studies have focused on
promoter DNA methylation in the context of tumour
suppressor gene silencing (for example, CDH1, RUNX3). In
contrast, very little is currently known about distal regulatory
elements (that is, enhancers) in GC.
Here, we analysed 435k predicted enhancer elements
identiﬁed through micro-scale histone modiﬁcation proﬁling of
primary gastric tumours, matched non-malignant tissues and
GC cell lines. Small-scale ChIP protocols are known to be
technically challenging and may sometimes result in signiﬁcant
between-sample variability. Reassuringly, we have previously
demonstrated that Nano-ChIP signals between tumours and
normal samples exhibit a good concordance with orthogonal
ChIP-qPCR results4 and in the present study we also performed
extensive quality control analyses, including variations in
mapping stringency, biological replicate analysis, promoter
ChIP enrichment and CHANCE analysis, to conﬁrm that the
vast majority (85–100%) of our Nano-ChIPseq libraries are of
acceptable quality. Our focus on recurrent epigenomic alterations
present in multiple samples further ensured that our biological
conclusions are likely to be robust, as shown by the observation
that 84% of the recurrent somatic gain predicted super-enhancers
were still rediscovered when analysis was conﬁned to only those
‘high-quality’ tumour/normal pairs passing both promoter-based
and CHANCE quality analysis. Nevertheless, we also note there is
still scope for improving the data quality of such experiments,
such as using spike-in approaches to better ascertain inter-
experimental variations or to exclude extreme experiments56.
Our study was motivated by recent studies in other cancer
types demonstrating a fundamental role for distal enhancers and
super-enhancers in cell identity and disease7,11,16,25,45. Indeed, in
our study and others11, recurrent predicted super-enhancers
largely manifested at known oncogenes and genes participating in
oncogenic processes (Fig. 2d). We also observed high levels of
enhancer variation between individual samples, exceeding
proximal promoter elements (Fig. 1d). When compared against
other tissues and tumour-types, almost 60% of GC predicted
super-enhancers were tissue-speciﬁc (Supplementary Fig. 15). It is
worth noting that in the current study we studied GCs as a
general category against matched non-malignant gastric tissues
for maximal sensitivity; however, recent studies have highlighted
distinct histopathological and molecular GC subtypes33–35.
Indeed, a preliminary analysis comparing recurrent somatic
gain predicted super-enhancers between 10 intestinal and 6
diffuse GCs identiﬁed 471 and 224 predicted super-enhancers
speciﬁc to intestinal- and diffuse-type GCs respectively, and 516
common predicted super-enhancers. These results also suggest
that there may exist distinct enhancer alterations in different
histological subtypes of GC. Such ﬁndings reﬂect the exquisite
tissue-speciﬁc nature of enhancer elements, and the consequent
need for generating comprehensive enhancer catalogues in
expanded patient cohorts and in many different tumour types.
The majority of samples analysed in our study were primary
tissues derived directly from patients, rather than in vitro cultured
cell lines. By comparing predicted enhancer activities (H3K27ac)
between tumours and matched normals, we were able to further
sub-classify cell line predicted super-enhancers according to their
somatic alteration status (somatic gain, somatic loss and
unaltered). Supporting their biological distinctiveness, the
subcategorized predicted super-enhancers also displayed speciﬁc
differences in other orthogonal features, including epigenomic
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patterns (H3K4me1, DNA methylation), gene transcription and
cancer hallmarks. Notably, in our data only a small fraction
of somatic gain predicted super-enhancers localized to regions of
copy number ampliﬁcation. Our results thus complement
recent studies implicating focal ampliﬁcation as a mechanism
for super-enhancer activity in cancer57. The ability to subclassify
predicted super-enhancers according to bona-ﬁde somatic
gain or loss is likely to improve downstream attempts to
pinpoint oncogenic mechanisms responsible for establishing
super-enhancers in cancer. Such approaches are also possibly
extendable to other disease states45.
A priori consideration of predicted super-enhancer
heterogeneity may also prove useful when analysing germline
variants associated with disease risk. While previous ﬁndings
have reported that disease-associated SNPs are generally
over-represented in regulatory elements7,9,11, we found that
somatic altered, but not unaltered predicted super-enhancers,
were speciﬁcally enriched in SNPs associated with cancer and
inﬂammatory gastrointestinal disease (a known risk factor for
gastrointestinal cancer). SNPs in these regions may alter disease
risk and cancer development through several non-exclusive
mechanisms, including modiﬁcation of TF binding motifs58,
regulation of long-range chromatin interactions26 or alteration of
H3K27ac levels. Indeed, in our study, we observed that two
SNPs associated with colorectal cancer (CRC) risk (rs10505477
and rs10411210)59 were also associated with local changes in
chromatin modiﬁcation in primary GCs. There are several
reasons why it may be plausible to integrate CRC risk data with
GC. First, at least one of these CRC risk SNPs (rs10505477)
has been reported to also inﬂuence GC clinical outcome in
both treatment response and patient survival60. Second, the key
TFs associated with the GC predicted super-enhancers (CDX2,
HNF4a) are also known to regulate colonic development61,62.
Third, the role of intestinal metaplasia (IM) as a pre-malignant
risk factor for GC is well-established, and in IM the gastric
epithelial cells adopt a cellular architecture and appearance
similar to colonic epithelium20. The observation that these
genetic variants, while present in germline DNA, may inﬂuence
chromatin structure and gene expression in the tumour has
also been observed in CRC63. These results further highlight
the importance of studying aberrant epigenetic states to reﬁne
our understanding of germline processes underlying disease
predisposition.
Our results suggest certain general principles regarding how
individual super-enhancers in GC might interact with the cis- and
trans-acting transcriptional machinery. Using two distinct
long-range chromatin interaction assays (Capture-C and 4C),
we observed several examples of somatic gain predicted
super-enhancers engaging both proximal and distal genes
exhibiting elevated tumour expression. It has been proposed that
genes linked to somatic gain predicted super-enhancers are
likely to occupy similar topological associating domains,
established through cohesin-mediated enhancer-promoter
loops64. The ability of somatic gain predicted super-enhancers
to inﬂuence both proximal and distal gene expression implicates
predicted super-enhancers as pivotal regulators of aberrant gene
expression in gastric tumours, which can contribute to disease
progression and chemoresponse35 (Fig. 5b). At the trans- level,
our data revealed that somatic gain predicted super-enhancers in
GC are associated with CDX2 and HNF4a occupancy. Previous
studies have shown that aberrant CDX2 expression in the
stomach is associated with intestinal metaplasia of the mucosal
epithelial cells, an important early event in gastric tumour
formation and that CDX2 has the potential to function as a GC
oncogene65. HNF4a has also been recently implicated in GC, as a
target of both the lineage-speciﬁc oncogenes KLF5 and GATA
factors52, and the AMPK signalling pathway20. Our results in
primary human tumours are supported by recent ﬁndings in the
mouse small intestine, where CDX2 has been found to regulate
HNF4a occupancy to control intestinal gene expression66.
Echoing these studies, we also found that CDX2/HNF4a
depletion effected chromatin alterations at local regions
concentrated at CDX2 and/or HNF4a binding sites. A potential
limitation in our study is that the modest albeit signiﬁcant
differences in H3K27ac observed after TF silencing may be due to
use of transient knockdown compared to stable gene silencing.
While it is thus possible that CDX2 and HNF4a may inﬂuence
GC super-enhancer activity in a more wide-spread manner, these
results nevertheless support a speciﬁc role for CDX2 and HNF4a
in GC predicted super-enhancer maintenance.
In conclusion, our study demonstrates a role for heterogeneity
in predicted super-enhancers and the utility of intersecting
chromatin proﬁles from primary tissues and cell lines to dissect
regulatory biology. This ﬁrst-generation roadmap of GC distal
enhancers now renders possible future integrative studies
involving transcriptional features associated with GC predicted
enhancers (eRNAs), and identifying somatic regulatory mutations
perturbing predicted super-enhancer activity67. We also note that
in this study, we have focused on heterogeneity between patients;
however, intra-tumour heterogeneity is also emerging as an
important mechanism of GC treatment resistance68. Future
studies should be focused on investigating the role of
epigenetic deregulation in GC intra-tumour heterogeneity.
Taken collectively, these studies will likely deepen our
knowledge of GC enhancer biology and regulatory circuits
underlying this deadly malignancy.
Methods
Primary tissue samples and cell lines. Primary patient samples were obtained
from the SingHealth tissue repository with approvals from the SingHealth
Centralised Institutional Review Board and signed patient informed consent.
‘Normal’ (that is, non-malignant) samples used in this study refers to samples
harvested from the stomach, from sites distant from the tumour and exhibiting no
visible evidence of tumour or intestinal metaplasia/dysplasia upon surgical
assessment. Tumour samples were conﬁrmed by cryosectioning to contain 440%
tumour cells. FU97, MKN7, OCUM-1 and RERF-GC-1B cell lines were obtained
from the Japan Health Science Research Resource Bank. KATO-III and SNU16
cells were obtained from the American Type Culture Collection. NCC-59 was
obtained from the Korean Cell Line Bank. YCC3, YCC7, YCC21, YCC22 were gifts
from Yonsei Cancer Centre, South Korea. Cell line identities were conﬁrmed by
STR DNA proﬁling performed at the Centre for Translational Research and
Diagnostics (Cancer Science Institute of Singapore, Singapore). STR proﬁles were
assessed according to the standard ANSI/ATCC ASN-0002-2011 nomenclature,
and the proﬁles of our cell lines showed 480% similarity to the reference
databases. MKN7 cells—one commonly misidentiﬁed line by ICLAC
(http://iclac.org/databases/cross-contaminations/) was conﬁrmed by showing a
perfect match (100%) with the MKN7 reference proﬁle in the Japanese Collection
of Research Bioresources Cell Bank. MycoAlert Mycoplasma Detection Kits
(Lonza) and MycoSensor qPCR Assay Kits (Agilent Technologies) were used to
detect mycoplasma contamination. All cell lines were negative for mycoplasma
contamination. For this study, we selected OCUM-1 and SNU16 cells as our main
cell line models for two reasons. First, OCUM-1 and SNU16 cells were originally
isolated from patients with poorly differentiated GC, and the majority of primary
GCs in our study are poorly differentiated (63%). Second, OCUM-1 and SNU16
have been previously used as GC models in many other published studies69,70, and
are thus regarded as accepted GC models in the ﬁeld. Thus, OCUM-1 and SNU16
were used as consistent cell line models for several experiments, including
Capture-C, 4C, enhancer CRISPR, TF binding and TF knockdown.
Nano ChIPseq. Nano-ChIPseq was performed as described4 with slight
modiﬁcations. For primary tissues, fresh-frozen cancer and normal tissues were
dissected using a razor blade in liquid nitrogen to obtain B5mg sized piece for
each ChIP. Tissue pieces were ﬁxed in 1% formaldehyde/PBS buffer for 10min at
room temperature. Fixation was stopped by addition of glycine to a ﬁnal
concentration of 125mM. Tissue pieces were washed three times with tris buffered
saline with EDTA (TBSE) buffer. For cell lines, 1 million fresh harvested cells were
ﬁxed in 1% formaldehyde/medium buffer for 10min at room temperature. Fixation
was stopped by addition of glycine to a ﬁnal concentration of 125mM. Fixed cells
were washed three times with TBSE buffer, and centrifuged (5000 r.p.m., 5min).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12983
12 NATURE COMMUNICATIONS | 7:12983 | DOI: 10.1038/ncomms12983 | www.nature.com/naturecommunications
Pelleted cells and pulverized tissues were lysed in 100 ml 1% SDS lysis buffer and
sonicated
to 300–500 bp using a Bioruptor (Diagenode). ChIP was performed using the
following antibodies: H3K4me3 (07-473, Millipore); H3K4me1 (ab8895, Abcam);
H3K27ac (ab4729, Abcam).
After recovery of ChIP and input DNA, whole-genome-ampliﬁcation was
performed using the WGA4 kit (Sigma-Aldrich) and BpmI-WGA primers.
Ampliﬁed DNAs were puriﬁed using PCR puriﬁcation columns (QIAGEN) and
digested with BpmI (New England Biolabs) to remove WGA adapters. Thirty
nanograms of ampliﬁed DNA was used for each sequencing library preparation
(New England Biolabs). Eight libraries were multiplexed (New England Biolabs)
and sequenced on two lanes of Hiseq2500 (Illumina) to an average depth of 20–30
million reads per library.
Sequence mapping and ChIP-seq density analysis. Sequence reads were
mapped against human reference genome (hg19) using Burrows-Wheeler Aligner
(BWA-MEM, version 0.7.0), after trimming the ﬁrst and the last ten bases prior to
alignment. Only high-quality mapped reads (MAPQZ10) were retained for
downstream analyses. The MAPQ value (Z10) was chosen as this has (i) been
previously reported to be a good value to use for good/conﬁdent read mapping71;
(ii) MAPQZ10 has also been indicated by the developers of the BWA-algorithm to
be a suitable threshold to use for conﬁdent mappings using their software72; and
(iii) studies assessing various algorithms for read alignment have also shown that
mapping quality scores do not correlate well with the likelihood of read mapping
being true/accurate and have shown that the level of accuracy obtained for
mapping accuracy plateaus between a 10–12 MAPQ threshold73. We also note
that in our study we have focused on recurrent predicted enhancers and super-
enhancers that are reliably detected in multiple samples, which increases the
robustness of our analysis. Sequencing coverage was computed using MEDIPS with
a 50 bp window size and read length extension to 200 bp. Peaks with signiﬁcant
ChIP enrichment (FDRo5%) relative to input libraries were detected using CCAT
(version 3). Peak densities within a region were computed by counting the total
number of mapped reads normalized by the library and region size, a metric
equivalent to reads per million mapped reads per kilobases (RPKM). This
normalization method adjusts for biases due to the higher probability of reads
falling into longer regions and has been applied in previous studies74. We thus
elected to apply RPKM-based normalization to make our study comparable to
these other studies. To account for background signals, read densities of each ChIP
library were corrected against the corresponding input library. Read densities
across samples were corrected for potential batch effects (for example, date of ChIP
assay) using COMBAT and to ensure equal sample variation. Of 17,360 recurrent
predicted enhancers detected in two or more cell lines, 98% were present in at least
one primary sample (normal or GC).
Quality control assessment of nano-ChIPseq data. We assessed qualities of the
ChIP libraries (H3K27ac, H3K4me3 and H3K4me1) using two different methods.
First, we estimated ChIP qualities, particularly H3K27ac and H3K4me3, by
interrogating their enrichment levels at annotated promoters of protein-coding
genes. Speciﬁcally, we computed median read densities of input and input-cor-
rected ChIP signals at 1,000 promoters associated with highly expressed protein-
coding genes. For each sample, we then compared read density ratios of H3K27ac
over input as a surrogate of data quality, retaining only those samples where the
H3K27ac/input ratio was greater than four-fold. Using these criteria, 48 out of 50
H3K27ac samples (GC lines and primary samples) exhibited greater than four-fold
enrichment, indicating successful enrichment. A similar analysis was also per-
formed for the H3K4me3 libraries (a promoter mark), and all 42 libraries satisﬁed
this quality control criteria. Second, we used CHANCE (CHip-seq ANalytics and
Conﬁdence Estimation)22, a software for ChIP-seq quality control and protocol
optimization that indicates whether a library shows successful or weak enrichment.
We found that the large majority (85%) of samples in our study exhibited
successful enrichment as assessed by CHANCE. The assessment status for each
library, as assessed by both methods, are reported in Supplementary Data 1.
We experimentally generated a second biological replicate of H3K27ac
Nano-ChIP-seq using KATO-III cells, and also compared our results against
independent H3K27ac KATO-III data generated from regular ChIP-seq
protocols23. The published sequencing reads were processed similarly to our
NanoChIP-seq libraries, excluding sequence trimming. Peaks detected by CCAT at
a FDR o5% were compared.
Chromatin accessibility and binding enrichment. Chromatin accessibility pro-
ﬁles of Epigenome Roadmap normal gastric tissues were obtained from the Gene
Expression Omnibus (GSM1027325, GSM1027320)28. Read densities of chromatin
accessibility proﬁles were computed for predicted enhancer regions and compared
against 100,000 randomly selected regions in RPKM units. We also computed
fractions of predicted enhancers overlapping open chromatin regions
(.narrowPeak) and active regulatory elements (H3K27ac, .gappedPeak) from 25
Roadmap chromatin accessibility and H3K27ac proﬁles. For TF binding
enrichment analysis, P300 and other TF binding coordinates curated by the
ENCODE (wgEncodeRegTfbsClusteredV3.bed), were downloaded from the UCSC
genome browser. Overlaps of at least 1 bp were identiﬁed using BEDTools intersect.
Levels of evolutionary sequence conservation were assessed using PhastConst
scores (Castelo R. phastCons100way.UCSC.hg19: UCSC phastCons conservation
scores for hg19. R package version 3.2.0). The maximum score within 500 bp
from the enhancer midpoint was used as the enhancer conservation score75.
Conservation scores were also computed for 10,000 randomly selected regions,
excluding pre-detected enhancer regions.
Identiﬁcation of predicted super-enhancers. Predicted enhancers were deﬁned
as enriched H3K27ac regions at least 2.5 kb from annotated TSS and also showing
enrichment of H3K4me1 and depletion of H3K4me3 (ref. 6). TSS annotations for
this study were derived from GENCODE version 19. H3K4me3/H3K4me1 log
ratios were computed using aggregated H3K4me3 and H3K4me1 signals from GC
cell lines and primary samples. Distal predicted enhancers exhibiting high
H3K27ac signals, but exhibiting high H3K4me3/H3K4me1 log ratios (42.4,
ref. 26) were classiﬁed as mistaken predictions and thus excluded from analyses.
Predicted enhancers were then further subdivided into predicted super-enhancers
or typical enhancers using the ROSE algorithm. Predicted super-enhancer regions
with at least one base overlap across multiple GC lines were merged using
BEDTools, and predicted enhancers localizing to regions distinct from the
predicted super-enhancer regions were termed predicted typical enhancers. The
presence of predicted typical or predicted super-enhancers in individual samples
was determined by the level of H3K27ac enrichment above background (Po0.01,
empirical test), the latter being the H3K27ac signal (in RPKM) from 100,000
randomly selected regions. To assign predicted enhancers/super-enhancers to
genes, we calculated distances from the predicted enhancer/super-enhancer centre
to the nearest active TSS, deﬁned as a promoter (500 bp ﬂanking at TSS) with
H3K27ac enrichment above randomly chosen regions11. Genes associated with
recurrent predicted super-enhancers were tested for oncogene enrichment using a
one-sided Fisher’s exact test. The top 500 oncogenes76 were used. To identify
recurrent predicted enhancer and predicted super-enhancers, the regions in each
GC line were ranked according to signal strength. The ranks of each predicted
enhancer/super-enhancer across the lines were multiplied to compute the rank
product. To determine the statistical signiﬁcance of the rank product, we compared
the observed rank product against a null distribution—ranks in each line were
reshufﬂed and the rank products computed. The reshufﬂing procedure was
repeated for 10,000 iterations. Observed rank products less than the null
distribution were considered statistically signiﬁcant.
Validation of predicted interactions. Super-enhancer/gene assignments were
validated using three orthogonal interaction data sets. These included:
(i) Predetermined interactions detected by PreSTIGE30 from 12 cell lines.
PreSTIGE interaction data were downloaded from the PreSTIGE website
(prestige.case.edu), involving cis-regulatory elements and target genes.
(ii) cis-regulatory elements/gene assignment by GREAT31 using the default
parameters.
(iii) Reference sets of enhancer-promoter interactions from RNAPII ChIA-PET
studies in K562, HCT-116, NB4, MCF-7, HeLa-S3 and GM12878 cells.
ChIA-PET interaction data were downloaded from encodeproject.org and
GSE72816. All interactions identiﬁed in each biological replicate were
considered for validation. These interactions involved two loci (anchors), one
of which is within 2.5 kb of a TSS and the other anchor overlapping predicted
super-enhancer regions found in our study.
Besides (i)-(iii), additional validation was performed using Capture-C analysis
on GC lines (see Fig. 4 of the Main Text).
Functional enrichment analysis. We used GOrilla32 to identify biological
processes (Gene Ontology annotations) enriched in recurrent predicted super-
enhancer/gene promoter or predicted typical enhancer/gene promoter interactions.
Default GOrilla parameters were used, and genes from GENCODE v19 were used
as background. To ensure comparability, predicted typical enhancers with the
highest H3K27ac across cell lines were selected to match the same number of
recurrent predicted super-enhancers. To select the former, predicted typical
enhancers were ranked in each line and were chosen based on the rank product
score. The most signiﬁcant terms (4 1.5-fold enrichment) associated with the
recurrent predicted super-enhancers were then compared against enrichment levels
associated with the top predicted typical enhancers. Besides GOrilla, we also
studied functional enrichments associated with recurrent predicted super-
enhancers and top predicted typical enhancers using GREAT using default
parameters, as GREAT provides correction against genes ﬂanked by larger
intergenic regions31. Signiﬁcant terms (also with 41.5-fold enrichment) were
ordered based on Binomial P-values.
Cell-line-derived super-enhancers in primary samples. Regions showing
H3K27ac enrichment or depletion of by two-fold or greater and with absolute
differences of greater than 0.5 RPKM4 were considered differentially present
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between GCs and matched normal samples. For PCA, we used signals from
predicted super-enhancers showing somatic gain in two or more patients. PCA
analysis was performed using R and plotted using the ‘pca3d’ package. We
estimated the required sample size to achieve 80% power and 5% type I error
(http://powerandsamplesize.com/) based on the average signals of 100 predicted
super-enhancers (Supplementary Data 2) from tumour and normal samples. This
result yielded a recommended sample size of 13 (average), which is met in our
study (19N/T). Three classes of predicted super-enhancers were deﬁned based on
the primary samples: (i) somatic gain, (ii) somatic loss and (iii) unaltered. Genes
associated with (i), (ii) and (iii) were mapped to gene groups previously reported in
Hnisz, 2013 (ref. 11), where each group is a compilation of several gene ontology
categories and used as a proxy for various cancerous hallmarks11. Statistical
signiﬁcance was computed using one-sided Fisher’s exact test in R. To assess
lineage-speciﬁcities of the recurrently gained somatic predicted super-enhancers
across different tissue types, we computed overlaps between the gastric predicted
super-enhancers against other non-gastric tissues11. An enrichment ratio with each
non-gastric tissue was computed based on the total observed overlap versus the
total overlap by chance.
Capture-C and data analysis. Capture-C was performed as previously descri-
bed36. Brieﬂy, 1 107 cells were crosslinked by 2% formaldehyde, followed by lysis,
homogenization, DpnII digestion, ligation and de-crosslinking. DNA was sonicated
using a Covaris to 150–200 bp to produce DNA suitable for oligo capture. Three
micrograms of sheared DNA was used for sequencing library preparation
(New England Biolabs). Predicted super-enhancer sequences were double captured
by sequential hybridization to customized biotinylated oligos (IDT, Supplementary
Data 5) and enrichment with Dynabeads (LifeTech). Captured DNA was
sequenced on an Illumina MiSEQ using the 150 bp paired-end conﬁguration.
Preprocessing of raw reads was performed to remove adaptor sequences
(trim_galore, http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)
and overlapping reads were merged using FLASH. In order to achieve short read
mapping to the hg19 reference genome, the resulting preprocessed reads were then
in-silico digested with DpnII and aligned using Bowtie (using p1, m2, best and
strata settings). Aligned reads were processed using Capture-C analyser36 to (i)
remove PCR duplicates, and (ii) classify subfragments as ‘capture’ if they were
contained within the capture fragment; ‘proximity exclusion’ if they were within
1 kb on either side of the capture fragment; or ‘reporter’ if they were outside of the
‘capture’ and ‘proximity exclusion’ regions. We additionally used the r3Cseq
package37 on the capture and reporter fragments to identify signiﬁcant interactions
of the viewpoint against a scaled background (Qo0.05, FDR) and also to compare
interaction proﬁles between different cell lines.
4C-seq and data analysis. 4C templates were prepared using previously
published protocols with slight modiﬁcations77. In brief, cultured cells were diluted
into single-cell suspensions, and chromatin was cross-linked with 1%
formaldehyde for 10min at room temperature. Cells were lysed and cross-linked
DNA was digested with the primary restriction enzyme HindIII-HF [R3104L, New
England Biolabs (NEB)]. Next, HindIII-digested DNA was subjected to proximity
ligation using T4 DNA ligase (EL0013, Thermo Scientiﬁc), followed by cross-link
removal using Proteinase K (AM2546, Ambion), yielding 3C libraries. The 3C
libraries were then subjected to a second restriction enzyme digestion using DpnII
(R0543L, NEB), followed by a circularization reaction using T4 DNA ligase. For
each viewpoint, 3.2 mg of the resulting 4C templates was used to perform a scale-up
inverse, nested PCR (Supplementary Table 5), of which 32 reactions (100 ng in
each) were pooled and puriﬁed using the MinElute PCR Puriﬁcation kit (Qiagen).
Ten micrograms of the PCR products were then run on 4–20% TBE PAGE gels
(5mg per well). On the gel, smears from 200 to 600 bp were excised and unwanted
PCR product bands were removed. DNA was then extracted from the cut-out gel
pieces for next-generation sequencing on an Illumina Miseq (2 250 bp).
Inverse primers were designed based on a viewpoint concept. The UCSC
Genome Browser (assembly: Feb. 2009 (GRCh37/hg19)) was used to locate the
region of interest. Upon addition of HindIII and DpnII tracks, two HindIII
restriction sites ﬂanking the region of interest were identiﬁed and the sequence
between the nearest HindIII and DpnII restriction sites were selected as the
viewpoint region. Based on this region, two pairs of primers (outer and nested)
were designed using the Primer-BLAST program (National Center for
Biotechnology Information (NCBI)) with the following adaptations to the default
settings: optimal primer melting temperature of 58 C, with a minimum of 55 C
and maximum of 60 C; GC content between 39 and 60%. Appropriate adaptors
(Nextera Index Kit—PCR primer, Nextera transposase sequence) and index
sequences were then added to the nested primer pair. Outer and nested primers
used in this study are presented in Supplementary Tables 4 and 5 respectively.
Primer sequences at the 50 ends of sequencing reads were trimmed using
TagDust2, and mapped to the reference genome (hg19) using Bowtie2 (2.2.6).
Unaligned reads were trimmed at the ﬁrst 50 base pairs before realigning them to
the reference genome. Only uniquely mapped reads with MAPQZ30 were used in
downstream analyses. Statistical signiﬁcant interactions (Qo0.05, FDR) were
detected using r3Cseq using a non-overlapping window approach (window
size¼ 5 kb). Signal plots of 4C data were generated using Basic4CSeq. Detected
interactions within DNA ampliﬁed regions were excluded. Interactions were then
mapped to genes, using promoters (þ / 2.5 kb from annotated TSSs from
GENCODE v19) overlapping with the interactions.
CRISPR/Cas9 enhancer deletions. CRISPR sgRNA target search was
performed using online software created by the Feng Zhang laboratory
(http://tools.genome-engineering.org). sgRNA pairs were designed to target
sequences ﬂanking enhancers identiﬁed for deletion. Brieﬂy, sequences
corresponding to 100 bp upstream/20 bp downstream of the 50 end of the enhancer,
and sequences corresponding to 20 bp upstream/100 bp downstream of the 30 end
of the enhancer, were used for the search. Top hits with the lowest level of coding
region off-target predictions were chosen. sgRNAs were cloned into the
pSpCas9(BB)-2A-GFP or -Puro vectors (Addgene). Brieﬂy, pairs of oligonucleo-
tides were designed and procured from Integrated DNA Technologies, Inc. for each
CRISPR target. Oligonucleotide pairs were then annealed to form DNA duplexes
containing overhangs on both sides for ease of cloning. Guide RNAs used to target
50 ends of individual enhancers were cloned into Bbs I-digested pSpCas9(BB)-2A-
GFP vectors, while sgRNAs targeting 30 ends of each enhancer were cloned into
Bbs I-digested pSpCas9(BB)-2A-Puro vectors. The inserts and vectors were ligated
using T4 DNA Ligase (New England Biolabs). DH5a cells were transformed with
the ligation product and plated on LB agar supplemented with ampicillin. Colonies
were picked and cultured, and plasmids extracted using the Wizard Plus SV
Minipreps DNA Puriﬁcation System (Promega). Sequences of plasmids were
conﬁrmed by performing Sanger sequencing. Oligonucleotides used for these
experiments are listed in Supplementary Table 6.
SNU16 and OCUM-1 cells were grown to 80–90% conﬂuence in Roswell Park
Memorial Institute (RPMI) supplemented with 10% fetal bovine serum (FBS), 1xP/
S and 0.5XNEAA. Cells were harvested and spun down, treated with Typsin for
5min at 37 degrees, and re-suspended by pipetting to achieve single cell
suspensions. Cell numbers were counted, and cells were washed once with 1 PBS
before resuspension in Resuspension buffer (R) at 1 107 cells/ml. For every
1 107 cells in 1ml of Resuspension buffer, 25 mg of pCas9-GFP-sgRNA and 25 mg
of pCas9-Puro-sgRNA plasmid were mixed with SNU16 or OCUM-1 cells.
Hundred microlitres of each cell suspension was electroporated using a 100 ml
Neon pipette in a Neon tube containing 3ml of Electrolytic Buffer (E2).
Electroporation conditions were: Pulse, V 1050, MS 30, Number 2. After
electroporation, cells were plated onto 8ml of RPMI supplemented with 10% FBS,
1xP/S and 0.5XNEAA. At 24 h after initial transfection, the cells were treated with
10 mg of Puromycin for 48 h, and the remaining GFP-positive cells were sorted
using FACS. The remaining surviving cells (both GFP-positive and Puromycin-
resistant) were then subsequently analysed using qPCR to estimate knockout
efﬁciencies.
We performed quantitative PCR (qPCR) to determine the efﬁciency of deletion
of individual enhancers in CRISPR/Cas9-targeted cells. Genomic DNA of targeted
and untargeted cells (pooled) was extracted using the AllPrep DNA Micro Kit
(QIAGEN) and subjected to qPCR in technical triplicates using KAPA SYBR FAST
qPCR Master Mix (Kapa Biosystems) on a CFX96 Touch Real-Time PCR
Detection System (Bio-Rad Laboratories, Inc.). Primers used in these reactions are
listed in Supplementary Table 6 (primers with ‘Int’ in their names were used for
this purpose). Relative amount of the speciﬁc targeted region present in the
genomic DNA samples was calculated using the comparative CT (DDCT) method,
normalized to the GAPDH gene and relative to untargeted cells.
Genomic DNA was extracted from the sorted cells using a previously described
protocol78. Brieﬂy, cells were triturated in 0.5 Direct-Lyse buffer (10mM Tris
pH 8.0, 2.5mM EDTA, 0.2M NaCl, 0.15% SDS, 0.3% Tween-20) and subjected
to the following heating and cooling program: 65 C for 30 s, 8 C for 30 s,
65 C for 1.5min, 97 C for 3min, 8 C for 1min, 65 C for 3min, 97 C for 1min,
65 C for 1min and 80 C for 10min. Subsequently, the lysates were diluted
approximately 4 in water and 3 ml of the diluted lysates were used to perform
20-ml PCR reactions using Taq DNA Polymerase (Life Technologies).
Primers used are in Supplementary Table 6 (primer pairs of ‘50 F’ and ‘30 R’
for each enhancer).
RT-qPCR to measure gene expression levels. Cells were FACS sorted for
GFP-positive cells and total RNA was extracted from cells using AllPrep
DNA/RNA Micro Kit (QIAGEN). Reverse transcription was performed on pooled
cells using iScript Select cDNA Synthesis Kit (Bio-Rad) with random primers.
qPCR was conducted using TaqMan Gene Expression Master Mix and TaqMan
probes (Applied Biosystems) on a CFX384 Touch Real-Time PCR Detection
System (Bio-Rad). All qPCR experiments were run in triplicate, and mean values
were used to determine mRNA levels. Relative quantiﬁcation was performed using
the comparative CT method with GAPDH as the reference gene and with the
formula 2-DDCT.
Copy number alterations and DNA methylation. Genomic DNAs from gastric
tumours and matched normal gastric tissues were hybridized on Affymetrix
SNP6.0 arrays (Affymetrix, Santa Clara, CA). Data in CEL format was processed in
the following order: (1) Normalization: Raw.CEL ﬁles were processed using
Affymetrix Genotyping Console 4.2. Reference models were created from SNP6.0
proﬁles of normal gastric tissues according to the hybridization batch. Copy
number changes in cell lines and primary tumour samples were determined by
using the reference model from primary normal samples. (2) Segmentation: Copy
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number segmentation data were produced using the circular binary segmentation
(CBS) algorithm implemented in the DNAcopy R package. The P-value cutoff for
detecting a change-point was 0.01, with a permutation number of 10,000. Copy
number gain and loss regions were deﬁned for showing average log ratios of40.6
ando 1.0, respectively. Illumina HumanMethylation450 (HM450) Inﬁnium
DNA methylation arrays were also used to assay DNA methylation levels.
Methylation b-values were calculated and background corrected using the
methylumi R BioConductor package. Normalization was performed using the
BMIQ method (watermelon package in R).
RNAseq and analysis. Total RNA was extracted using the Qiagen RNeasy Mini
kit. RNA-seq libraries were constructed according to manufacturer’s instructions
using Illumina Stranded Total RNA Sample Prep Kit v2 (Illumina, San Diego, CA)
Ribo-Zero Gold option (Epicentre, Madison, WI) and 1 mg total RNA. Completed
libraries were validated with an Agilent Bioanalyzer (Agilent Technologies, Palo
Alto, CA) and applied to an Illumina ﬂow cell via the Illumina Cluster Station.
Sequencing was performed using the paired-end 101 bp read option. RNA-seq
reads were aligned to the human genome (hg19) using TopHat2-2.0.12 (default
parameter and --library-type fr-ﬁrststrand). The per base sequence quality and
per sequence quality scores of the mapped reads was assessed using FastQC version
0.10.1 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Transcript
abundances at the gene level were estimated by cufﬂinks. Gene expression from
primary samples showing variation greater than zero was corrected for potential
batch effects using ComBat. Gene expression values were measured in FPKM units.
Differential expression between groups was identiﬁed as genes showing altered
expression by at least two-fold and absolute differences of 0.5 FPKM.
Survival analysis. GC samples from seven independent studies were clustered
using a K-medoids approach. Only genes with expression values in all seven studies
were used in analyses. Kaplan–Meier survival analysis was employed with overall
survival as the outcome metric. Log-rank tests were used to assess the signiﬁcance
of Kaplan–Meier curves. Multivariate analysis involving additional variables, such
as age, tumour stage, Lauren’s histological subtypes and locality (Asian versus
Non-Asian), was performed using Cox regression.
Disease-associated SNP analysis. Trait-associated SNPs were downloaded from
the UCSC browser of GWAS (27 August 2015). For this study, we focused on SNPs
occurring in noncoding regions and excluded SNPs within coding regions. We
computed overlaps between SNPs from each trait/disease and somatic predicted
super-enhancers using BEDtools ‘intersect’ (nGWAS), and compared nGWAS
against the total number of disease-associated SNPs outside the predicted super-
enhancers (nGWAS’). As an additional control, we created an ‘SNP background’
model using a set of all SNPs from two commonly used SNP arrays (Illumina
HumanHap550 and Affymetrix SNP6). The number of SNPs from the SNP
background overlapping the predicted super-enhancers was calculated (nBack-
ground) and compared against the total number of background SNPs outside the
predicted super-enhancers (nBackground0). The ratio of normal SNPs in predicted
super-enhancers was computed as nBackground/nBackground0 . Expecting that the
increased number of disease-associated SNPs in predicted super-enhancers is
associated with a high prevalence of SNPs in these regions, our null hypothesis is
therefore that there is no difference between the ratio of disease-associated SNPs
and the ratio of normal SNPs (enrichment ratio). Chi-square tests were conducted,
with enrichment P-values ofo0.01 considered statistically signiﬁcant. To under-
stand the relationship between risk-associated SNPs and histone modiﬁcation, we
identiﬁed validated SNPs in gastrointestinal diseases (for example, ulcerative colitis
and colorectal cancer) found to be associated with disease in at least two inde-
pendent studies. Samples were classiﬁed into two groups based on the presence of
the disease-associated SNPs, using GATK Uniﬁed Genotyper. Differences of
H3K27ac signals between tumour and matched normal in samples with or without
disease-associated SNPs were compared.
TF binding motif analysis. We interrogated enrichments of TFs in somatic gain
predicted super-enhancers and unaltered predicted super-enhancers using the
ReMap database48. Transcription factor binding sites with at least 60% of overlap
with predicted super-enhancers were counted, and the ranks of the top 10 most
enriched TFs compared. Binding densities of TFs were computed as the total
binding sites detected in the regions divided by the total size of the regions in unit
of million base pairs (Mbp). For CDX2, we examined CDX2 binding sites in
recurrently gained somatic predicted super-enhancers to predict nearby binding of
other TFs, using HOMER with default parameters49. The top 20 TF identiﬁed from
the HOMER outputs were used for expression correlation analysis. Additionally,
we also identiﬁed CDX2 co-binding motifs using PScanChIP50 with JASPAR 2016.
Expression correlations (Spearman’s correlation) between CDX2 and potential
co-binding partners were evaluated.
siRNA transfection. ON-TARGETplus Human siRNA SMARTpools (HNF4a and
CDX2), individual ON-TARGETplus Human individual siRNAs (HNF4a) and
ON-TARGETplus Non-targeting siRNA controls (Dharmacon/Thermo Fisher
Scientiﬁc) were used to transfect cells (2 105) at 50 nM in 6-well plate, using
Dharmafect 1 transfect reagent, according to the manufacturer instructions.
Knockdown efﬁciency after 72 h RNAi treatment was examined using quantitative
RT-PCR and/or Western Blot analysis (Supplementary Fig. 17).
Western blotting. Cells (2 105) were harvested in RIPA buffer (Sigma) and
lysed for 10min on ice. Concentration of supernatants was measured using Pierce
BCA protein assay (Thermo Scientiﬁc). CDX2 (1:500; MU392A-UC, Biogenex),
HNF4a (1:1,000; sc-8987, Santa Cruz Biotechnology) and GAPDH (1:3,000;
60,004-1-Ig, Proteintech Group) antibodies were used to probe the lysate.
Quantitative RT-PCR. Total RNA was isolated using RNeasy Mini Kit (Qiagen),
and DNA was removed using RNase-Free DNase Set (Qiagen). Two micrograms
RNA was reverse transcribed using Superscript III First Strand Synthesis System
(Invitrogen), and complementary DNA was ampliﬁed using SYBRGreen PCR
Master Mix (Applied Biosystems). Fold changes were normalized to GAPDH.
Primer sequences are as follows: HNF4a: F1-50 GTGCGGAAGAACCACAT
GTACTC 30 , R1-50 CGGAAGCATTTCTTGAGCCTG 30, F2-50 CTGCAGGCTC
AAGAAATGCTT 30 , R2-50 TCATTCTGGACGGCTTCCTT 30 , F3-50
TGTCCCGACAGATCACCTC 30, R3-50 CACTCAACGAGAACCAGCAG 30 ;
CDX2: F1-50 GCAGCCAAGTGAAAACCAGG 30 , R1-50 CCTCCGGATGGT-
GATGTAGC 30 , F2-50 AGTCGCTACATCACCATCCG 30 , R2-50 TTCCTCTC
CTTTGCTCTGCG 30; GAPDH: F-50 CCAGGGCTGCTTTTAACTC 30 , R-50
GCTCCCCCCTGCAAATGA 30.
CDX2 and HNF4a ChIP-seq and analysis. Cells were cross-linked with 1%
formaldehyde for 10min at room temperature, and stopped by adding glycine to a
ﬁnal concentration of 0.2M. Chromatin was extracted and sonicated to 500 bp.
CDX2 (MU392A-UC, Biogenex) and HNF4a (sc-8987, Santa Cruz Biotechnology)
antibodies were used for chromatin immunoprecipitation (ChIP). ChIPed DNA
(10 ng) was used for ChIP with DNA sequencing (ChIP-seq) library construction
following manufacturer protocols (New England Biolabs). Input DNA from cells
prior to immunoprecipitation was used to normalize ChIP-seq peak calling. Prior
to sequencing, qPCR was used to verify that positive and negative control ChIP
regions ampliﬁed in the linear range. Size distributions of the library samples were
checked using a Bio-analyzer (Agilent Technologies). In an initial analysis
comparing recurrently gained predicted super-enhancers speciﬁc to intestinal and
diffuse-type GCs (10 intestinal, 6 diffuse), we did not observe any signiﬁcant
differences in CDX2 binding between the two subtypes. A deeper analysis revealed,
however, high within-subtype variability in CDX2 expression between individual
tumours of the same subtype, consistent with previous reports that CDX2
expression is not absolutely associated with intestinal subtype GC79. We thus
performed a complementary analysis where the GCs were ordered by their
individual CDX2 expression levels and examined. CDX2 binding density were then
computed at recurrent somatic gain predicted super-enhancers identiﬁed in GC
samples showing high (n¼ 8) and low (n¼ 8) CDX2 expression. In differential
binding signal analysis, we computed binding signals for CDX2 and HNF4a for
200 bins spanning those predicted super-enhancers showing somatic gain or no
alteration in primary samples and also detected in OCUM-1 or SNU16 cell lines.
Signals were measured in RPKM units. To estimate the effect of TF knockdown on
H3K27ac strength, we deﬁned an internal control comprising observed variation of
H3K27ac signals between independent wild-type (WT) samples. We then
measured differences between WT samples against TF-silenced (siCDX2, siHNF4a,
or double TF) samples, which were then compared against this background
variation. Subregions with differences499% of background variation were termed
as H3K27ac depletion; while differenceso1% of the background variation were
termed as H3K27ac gain. Statistical enrichments of H3K27ac-depleted subregions
corresponding to predicted super-enhancers were conducted using one-sided
Fisher’s exact test. To study relationships between the differential regions and their
distances to nearby CDX2/HNF4a binding sites, the regions were also segregated
into three categories (near, moderate, distal) based on their distance distribution.
Mid-point locations between the CDX2 and HNF4a summits were used to analyse
distances between H3K27ac-depleted subregions and CDX2-HNF4a cobinding
sites. To study associations between gene expression and somatic gain predicted
super-enhancers in TF-silenced cells, we selected genes linked to predicted
super-enhancers exhibiting signiﬁcant positive expression correlations with
H3K27ac predicted super-enhancer signals in primary samples (r40.4; Po0.05,
two-sided t-test) and also observed in the GC cell lines. To assess the signiﬁcance of
TF knockdown on predicted super-enhancer target gene expression, we used a
permutation approach. Speciﬁcally, focusing on predicted super-enhancers
exhibiting H3K27ac depletion after TF silencing, we permuted the actual
super-enhancer to gene assignments 10,000 times. An empirical P-value was then
derived by counting the number of times the number of downregulated genes in
the permuted gene/super-enhancer set exceeded the experimentally observed
number of downregulated genes in the actual gene/super-enhancer set.
Data availability. Histone NanoChIP-seq (GSE76153 and GSE75898), SNP array
(GSE85466), RNA-seq (GSE85465) and DNA methylation data (GSE85464)
generated during this study have been deposited in Gene Expression Omnibus.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12983 ARTICLE
NATURE COMMUNICATIONS | 7:12983 | DOI: 10.1038/ncomms12983 |www.nature.com/naturecommunications 15
Previously deposited histone ChIP-seq (GSE51776 and GSE75595) and SNP array
(GSE31168 and GSE36138) data that are used in this study are available in Gene
Expression Omnibus. Chromatin accessibility proﬁles of normal gastric tissues
from Epigenome Roadmap were obtained from the Gene Expression Omnibus
(GSM1027325, GSM1027320). RNAPII ChIA-PET data analysed in this study was
obtained from encodeproject.org and Gene Expression Omnibus (GSE72816). The
authors declare that all other data are available within the Article or associated
Supplementary information ﬁles, or available from the author on request.
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